Drugs / rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Trials 13
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-05-19 | Lisata Therapeutics, Inc. | Results Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease lisata.com ↗
Based on their assessment of the data, the IDMC approved proceeding with the enrollment of the remaining four patients in the study without further review. |
| 2021-06-22 | Lisata Therapeutics, Inc. | Regulatory Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease lisata.com ↗
FDA authorizes new IND for the study of CLBS201 in patients with reduced kidney function |
| 2021-03-08 | Lisata Therapeutics, Inc. | Regulatory Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease lisata.com ↗
We are very pleased that the FDA has granted orphan drug designation to CLBS12 in Buerger’s disease. |
| 2020-04-23 | Lisata Therapeutics, Inc. | Regulatory Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage lisata.com ↗
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the U.S. Food and Drug Administration (“FDA”) has authorized its investigational new drug (“IND”) application for the study of CLBS119, a CD34+ cell therapy for repair of COVID-19 induced lung damage. |
All press releases naming this drug 8 releases
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02337985 ↗ |
| Known as | Base-edited hematopoietic stem and progenitor cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06325709 ↗ |
| Known as | CLBS119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04522817 ↗ |
| Known as | CLBS12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02501018 ↗ |
| Known as | CLBS14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00300053 ↗ |
| Known as | CLBS201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990427 ↗ |
| Known as | Cultured retinal stem and progenitor cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05187104 ↗ |
| Known as | Genetically Engineered Hematopoietic Stem/Progenitor Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03157804 ↗ |
| Known as | stem and progenitor cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02437708 ↗ |
| Known as | Tendon stem/progenitor cells | “Therefore, this study intends to first culture and expand tendon stem/progenitor cells (TSPCs) to form therapeutic agents, then apply TSPC-enhanced therapy intraoperatively to...” NCT07320378 ↗ |
| Known as | TSPCs | “Therefore, this study intends to first culture and expand tendon stem/progenitor cells (TSPCs) to form therapeutic agents, then apply TSPC-enhanced therapy intraoperatively to...” NCT07320378 ↗ |
| Action | Restore | “in order to restore their hematopoiesis with genetically corrected stem cells” NCT03157804 ↗ |
| Modality | Cell therapy | “Autologous CD34+ cell therapy was associated with persistent improvement in angina at 2 years” PMID 27151378 ↗ May 2016 |
| Route | Other | “Autologous CD34+ cells will be delivered in 10 intramyocardial injections” NCT00300053 ↗ |
| Target | FANCA | “lentiviral vector carrying the gene FANCA” NCT03157804 ↗ |